Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy
    6.
    发明申请
    Endothelin Single Nucleotide Polymorphisms and Methods of Predicting B-Adrenergic Receptor Targeting Agent Efficacy 审中-公开
    内皮素单核苷酸多态性和预测B肾上腺素能受体靶向剂功效的方法

    公开(公告)号:US20150366843A1

    公开(公告)日:2015-12-24

    申请号:US14746362

    申请日:2015-06-22

    IPC分类号: A61K31/4045

    摘要: The present invention concerns the use of methods for evaluating β-adrenergic receptor targeting agent treatment for a patient, particularly one with a heart condition. In general, the disclosed methods entail determining the presence or absence of one or more polymorphisms in an endothelin gene system member. Based on the results of this determination, a β-adrenergic receptor targeting agent may be prescribed, administered or a treatment regimen altered, including the administration of a β-blocker. Accordingly, methods of treatment are also described.

    摘要翻译: 本发明涉及用于评估患者,特别是患有心脏病的患者的肾上腺素能受体靶向剂治疗方法的用途。 通常,所公开的方法需要确定内皮素基因系统成员中存在或不存在一种或多种多态性。 基于该测定的结果,可以规定,给药或改变治疗方案,包括给药一种β-阻滞剂的β-肾上腺素能受体靶向剂。 因此,还描述了治疗方法。